FDA Rejects Schering-Plough's Anaesthetic Drug Sugammadex NDA The U.S. FDA has issued a non-approvable letter to Schering-Plough regarding the U.S. firm's New Drug Application (NDA) for sugammadex sodium. The product (also marketed under the brand Bridion) is a selective relaxant binding agent that reverses the effects of neuromuscular blockade by rocuronium in general anaesthesia. In a press statement, Schering-Plough has said that the FDA's concerns over the drug are related to hypersensitivity or allergic reactions.
Source: www.medicalnewstoday.comMake Sure 'Express LIFTs' Reach The Right Destination, UK In response to the Department of
Health announcement that it intends to streamline and speed up the procurement process for LIFT developments, the NPA is seeking assurance from PCTs that corners will not be cut in planning and public consultation to meet deadlines. DH has stated that procurement processes for LIFT sites that have in the past lasted for two years will now be shortened to six weeks.
Source: www.medicalnewstoday.comOrthokine Treatment Is Effective For Knee Arthritis, Even After Two Years - Long-Study Confirms Effectiveness Of Autologous Therapy The results of a two-year representative study of osteoarthritis of the knee, published in the internationally renowned journal "Osteoarthritis and Cartilage", confirm the safety and effectiveness of Orthokine therapy, in which anti inflammatory proteins obtained from the patient's own blood are injected into the arthritic joint.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 AM
